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The rationale for preventing cancer 




Cachexia commonly occurs at the terminal stage of cancer and has largely unclear molecular mechanisms. A recent 
study published in Nature Medicine, entitled “Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia,” 
reveals that cachectic cancer cells can secrete multiple cytokines that induce excessive fatty acid oxidation, which is 
responsible for muscle loss in cancer cachexia. Inhibition of fatty acid oxidation using etomoxir can increase muscle 
mass and body weight in cancer cachexia animal models. The usage of stable cachexia animal models is also dis‑
cussed in this research highlight.
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In the terminal stages of many chronic diseases, includ-
ing cancer, loss of body mass may occur, which cannot 
be prevented or corrected by nutritional supplementa-
tion. This condition is termed cachexia, defined as  >5% 
weight loss within 6  months. In addition to the loss of 
adipose tissue and overall metabolic imbalance, a typi-
cal characteristic of cachexia is muscle atrophy, resulting 
in fatigue and fetal weakness. Cancer cachexia is com-
monly observed in up to 80% of patients with advanced-
stage disease and is one of the primary causes of can-
cer-related morbidity and mortality [1–3]. In fact, in 
cancer patients receiving radical therapy, cachexia can 
also occur. In patients with nasopharyngeal carcinoma 
from endemic areas, whose tumors are naturally sensitive 
to radiotherapy [4, 5], cachexia can be induced by radi-
cal radiotherapy in patients with post-irradiation naso-
pharyngeal necrosis [6]. Even worse, cachexia can usually 
induce resistance against conventional anti-cancer thera-
pies, and no drug has been approved to treat or prevent 
cachexia in current medical practice [7].
It is believed that early diagnosis of and interven-
tion in cancer cachexia can control its fetal progression, 
improve a patient’s quality of life, and prolong survival 
[8]. However, the underlying molecular mechanisms 
of cancer cachexia are largely unclear, preventing the 
development of effective intervention approaches. In a 
study recently published in Nature Medicine, entitled 
“Excessive fatty acid oxidation induces muscle atrophy in 
cancer cachexia,” Fukawa et  al. [9] report their interest-
ing findings that cachectic cancer cells secrete multiple 
inflammatory factors, including interleukin-6 and tumor 
necrosis factor-alpha, which have been suspected to play 
roles in cancer cachexia for decades [10, 11]. This secre-
tion results in fatty acid oxidation and activation of a p38 
stress-response signature in the skeletal muscles before 
presentation of cachectic muscle atrophy.
In this study, the authors also demonstrate that blockade 
of fatty acid oxidation using etomoxir can rescue human 
myotubes in vitro and can increase muscle mass and body 
weight in cancer cachexia animal models [9]. Therefore, 
targeting fatty acid-induced oxidative stress has a great 
potential for preventing cancer-induced cachexia.
The application of stable cachexia animal models is 
one of the strengths of this study. As shown in Fig. 1, the 
human clear cell renal cell carcinoma cell line RXF393 
can stably induce cachexia in nude mice after several 
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weeks of subcutaneous inoculation or orthotopic inocu-
lation of the cancer cells into the subrenal capsule area.
Much more information can be found in the authors’ 
dataset from high-throughput expression profiling of 
human myotubes after exposure to cachectic or non-
cachectic conditioned media [9]. The involvement of 
multiple cytokines reported in this comprehensive study 
also indicates that certain other causal factors may play 
a role in cancer cachexia, and especially those factors 
responsible for adipose tissue rearrangement.
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Fig. 1 Different clear‑cell renal cell carcinoma (ccRCC) cell lines have different biological behaviors after orthotopic inoculation of the cancer cells 
into the subrenal capsule area. Inoculation of cancer cells into the subrenal capsule area of nude mice to generate an orthotopic renal cancer 
model was applied to evaluate the different biological behaviors of ccRCC cells. The tumor composed of the RXF393 cell line induced cachexia in 
the host, leading to a moribund condition, even when the primary tumor was small (green dashed circle). The tumor composed of the SN12C cell 
line could not induce cachexia or metastasis, even when the primary tumor was very large (green dashed circle). The tumor composed of the SKRC39 
cell line could generate heavy lung metastases (blue dashed line), but not cachexia
